Atenolol
ADVERTISEMENT
- Molecular formula
- C14H22N2O3
- CAS Number
- 29122-68-7
- IUPAC Name
- N-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide
- Molecular Weight
- 266.34g/mol
- Melting Point
- (Celsius)
- Boiling Point
- (Celsius)
- Density
- 1.1800g/cm3
- Synonyms
- practolol
Identification
Interesting facts
Interesting Facts about N-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide
N-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide is a fascinating compound that plays a significant role in medicinal chemistry and pharmaceuticals. Here are some interesting points to consider:
- Pharmacological Properties: This compound is recognized for its potential use in various therapeutic applications, particularly as an analgesic and anti-inflammatory agent. Its structure allows for interactions with biological targets that modulate pain perception.
- Structure-Activity Relationship: The unique arrangement of functional groups, including the isopropylamino moiety, affords the compound its activity. Understanding how modifications to these groups influence efficacy is crucial for drug design.
- Hydrophilicity: The presence of a hydroxyl group enhances the compound's solubility and interactions with biological membranes, making it a valuable candidate for formulation in drug delivery systems.
- Research Applications: Ongoing research is focusing on the optimization of its pharmacokinetic profile, aiming to increase its bioavailability and reduce potential side effects.
- Historical Context: Compounds similar to N-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide have been pivotal in the development of non-steroidal anti-inflammatory drugs (NSAIDs), which are crucial in managing pain and inflammation globally.
As a student of chemistry or a scientist, it’s fascinating to explore the depth of this compound’s applications and the ongoing research that continues to unveil its full potential. The synthesis and modification of such compounds are essential in advancing medical science and improving patient outcomes.